Hexoskin Medical System - ECG Performance Testing

Sponsor
Carré Technologies Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05970328
Collaborator
(none)
60
2
2
30
14.7

Study Details

Study Description

Brief Summary

The goal of this observational study is to validate the efficacy of the Hexoskin Medical System (HMS) for its intended use (i.e., manual assessment of cardiac rhythm disturbances) in non-critical adult participants that are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor. The main question it aims to answer are:

  1. Whether the HMS ECG recordings can be used to accurately detect cardiac beats when compared with the Holter monitor

  2. Whether there are high correlations between the HMS and Holter monitor in ECG characteristics

  3. Whether the HMS ECG recordings can be used to accurately classify cardiac rhythm/rhythm disturbance when compared with the Holter monitor

  4. What is the accuracy of using HMS ECG recordings to detect cardiac beats

  5. What is the accuracy of using HMS ECG recordings to identify cardiac rhythm/rhythm disturbance

Participants will wear the HMS and the Holter monitor at the same time to record ECG signals. Researchers will evaluate the ECG recordings acquired from both devices and assess the above questions.

Condition or Disease Intervention/Treatment Phase
  • Device: Hexoskin Medical System

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
HMS ECG Clinical Validation Study - Protocol External Site
Actual Study Start Date :
Jul 24, 2023
Anticipated Primary Completion Date :
Sep 24, 2023
Anticipated Study Completion Date :
Sep 24, 2023

Arms and Interventions

Arm Intervention/Treatment
Arrhythmia Participant

Non-critical adult (21 years and older) participants that are suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.

Device: Hexoskin Medical System
Participant wears both the Hexoskin Medical System and the Nasiff Holter Monitor at the same time to acquire ECG recordings.
Other Names:
  • Nasiff Holter Monitor
  • Outcome Measures

    Primary Outcome Measures

    1. Cardiac beat detection agreement [2 days]

      The level of agreement between using the HMS and the Holter monitor (reference standard) ECG recordings in detection of beats

    Secondary Outcome Measures

    1. ECG characteristics measurement agreement [2 days]

      The agreement (as evidenced by establishment of a positive linear relationship) of Holter monitor(reference standard) and HMS to measure each of the eight (8) ECG Characteristics. ECG characteristics measured in this study include: RR Interval (ms), PR Interval (ms), PP Interval (ms), QRS Duration (ms), QRS Amplitude (mV), P Wave Duration (ms), P Wave Amplitude (mV), and QT Interval (ms).

    2. Cardiac rhythm outcome agreement [2 days]

      The agreement of using Holter monitor (reference standard) and HMS ECG recordings to detect cardiac rhythms or rhythm disturbances.

    3. Cardiac beat detection accuracy [2 days]

      The Sensitivity and Positive Predictive Value (PPV) of using the HMS ECG recordings to detect cardiac beats.

    4. Cardiac rhythm identification accuracy [2 days]

      The Sensitivity and PPV of using the HMS ECG recordings to identify cardiac rhythm/rhythm disturbance.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 100 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Provision of signed and dated informed consent form.

    • Stated willingness to comply with all study procedures and availability for the duration of the study.

    • Male or female, aged 21 years or older.

    • Participants must be suspected of having an arrhythmia or have evidence of arrhythmia requiring monitoring via 24-hour Holter monitor.

    Exclusion Criteria:
    • Body circumference that is not covered by the HMS Shirt sizing chart

    • Presence of pacemaker or Implantable Cardioverter-Defibrillator (ICD) devices

    • Known allergic reactions to silver or polyamide/polyester/elastane

    • Known allergic reactions to ECG gel electrodes

    • Documented medical condition or illness requiring intensive medical treatment or care

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lawrence Park Cardiology Toronto Ontario Canada M4N 3N1
    2 Yorkview Cardiology North York Canada

    Sponsors and Collaborators

    • Carré Technologies Inc.

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Carré Technologies Inc.
    ClinicalTrials.gov Identifier:
    NCT05970328
    Other Study ID Numbers:
    • HMS_ECG_external
    • 361070
    First Posted:
    Aug 1, 2023
    Last Update Posted:
    Aug 2, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Carré Technologies Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 2, 2023